Psylo

Our CEO 🧪 Joshua Ismin had the pleasure of sitting down with Josh Hardman from Psychedelic Alpha for an insightful chat about our recent successful $8M seed financing round. In this mini-interview, Josh discusses: 🚀 Plans to advance our neuroplastogen program, PSYLO-100X, into clinical trials. 🔬 Our unique target-based approach to non-hallucinogenic drug discovery. 🧠 Indication selection with a flexible, evidence-informed strategy. 📅 Timeline for entering clinical trials. 🤔 What makes a psychedelic a psychedelic and how Psylo is pioneering in the neuro space with our innovative neuroplastogens. 🙏 A big thank you to Josh Hardman and Psychedelic Alpha for the feature. See the full interview to learn more about our groundbreaking work and future plans: https://lnkd.in/enpKE6Bk #Psylo #Biotech #5HT2A #Neuroplastogens #Innovation #ClinicalTrials

We're thrilled to announce our US$8 million seed round and plans to shift our headquarters to the U.S. "The goal is to just maximize the incentives that are available in various countries and take advantage of the best talent we can draw to the company," says 🧪 Joshua Ismin, CEO and co-founder of Psylo. We are excited to share an exclusive interview with Joshua Ismin in Capital Brief, where he shares Psylo's vision and journey. Discover how our recent US$8 million seed funding round is not only growing the company but setting the stage for a revolutionary approach to mental health. Josh details our strategy for expanding into the U.S. while maintaining a strong presence in Australia’s dynamic research environment, effectively leveraging the unique advantages of both ecosystems. 👀 Read the full article to learn how Psylo is navigating the biotech landscape to bring groundbreaking mental health solutions to the forefront: https://lnkd.in/ggPiAXQ9 This is an essential read for anyone interested in the nexus of biotech and mental health innovation! Special thanks to Hugo Mathers and the Capital Brief for their insightful coverage and for helping us share our story. #Psylo #Biotech #MentalHealth #CNS #Innovation #5HT2A #StartupLife

📣 Exciting update on psychedelic clinical trials. In case you missed it in the May edition of our Neuroscience Newsletter, we're bringing the latest advancements in psychedelic research directly to your feed! 🧠 Key Insights: - A remarkable increase in the number of psychedelic clinical trials. - Progress across different phases of clinical research, signaling advancements towards potential regulatory approvals. - The range of conditions being targeted is broadening, underscoring the versatility of psychedelic therapies. - Exciting developments such as the integration of psilocybin with neuromodulation devices. 👀 Read the article for a comprehensive analysis of these developments and understand how they are setting the stage for future therapies.

We are proud to see Psylo and our CSO, 💊 Sam Banister, featured in Scientific American. The article explores the evolving landscape of psychedelic research and Psylo’s innovative approach to developing non-hallucinogenic treatments for mental health. Sam discusses the significant advancements and the increasing interest in this field, which is not just about transforming mental health treatment but also about tailoring these powerful therapies to be more accessible for patients. Read the full article here for an in-depth look at how we're shaping the future of mental health: https://lnkd.in/eaWzGF7h #Psylo #MentalHealth #Biotech #Innovation #ScientificAmerican #5HT2A

We couldn't agree more! Nature Portfolio’s Nature Biotechnology explores next-generation psychedelics, with talking points from our portfolio company Psylo CSO Sam Banister. Congrats on getting the word out on an important issue for mental health disorders! #nature #biotech #5ht2a #mentalhealth https://lnkd.in/dVpzeRTm

Well done 💊 Sam Banister on the great write-up in Nature Biotechnology! I'm incredibly proud to be featured alongside some of the most well-funded and innovative startups focused on neuroplastogens (what we used to call next-generation psychedelics). In the table on page 2, some remarkable companies with big numbers next to them: Seaport Therapeutics recently announced a $100m raise Delix Therapeutics has raised over $100m Reunion Neuroscience announced a $103m raise earlier this year Cybin Inc announced a $150m raise earlier this year Gilgamesh Pharmaceuticals announced a deal with Abbvie worth $2bn Who knows where the next $100m goes but my money is on Psylo (and Lophora!)

We're excited to share Psylo's partnership with Dr Nick Everett, from the University of Sydney’s Brain and Mind Centre, to pioneer innovative treatments for neuropsychiatric disorders by leveraging advanced artificial intelligence technologies. This collaboration combines our cutting-edge artificial intelligence platform with the university’s world-class research expertise. Our goal is to accelerate the development of mental health treatments that are not only safer and more effective but also accessible to those in need. Dr Nick Everett – an NHMRC Emerging Leader, Research Fellow at the University’s School of Psychology and an expert in behavioural neuroscience – has been awarded a partnership grant by the Brain and Mind Centre to lead this initiative. We are privileged to work alongside Dr Everett, who has developed an innovative machine-learning-guided behavioral analysis platform. Psylo will use this powerful technology to enhance our drug development process, increasing both capacity and efficiency. “By combining our machine-learning models with Psylo's cutting-edge platform, we aim to develop more effective and safer treatments for mental health conditions, at a pace faster than previously possible," said Dr Nick Everett. Psylo's co-founder and CSO, 💊 Sam Banister, added, “Our proprietary computational platform has successfully optimised next-generation drug candidates that retain the therapeutic benefits of natural psychedelics in preclinical models. The expertise provided by Dr Everett and the University will be invaluable in accelerating the translation of these compounds into viable treatments for patients." 🧪 Joshua Ismin, Psylo's co-founder and CEO, commented, “The treatments we are developing could redefine how we treat depression, anxiety, and other central nervous system disorders. Through this partnership, we can use machine-learning approaches to expedite the development of these promising therapeutics to address this tremendous unmet need.” 👏 Join us in celebrating this partnership, set to revolutionize the treatment of central nervous system disorders. 👀 Read the full story here: https://lnkd.in/gt3gyRQ3 #Psylo #USYD #Biotech #MentalHealth #CNS #5HT2A

"The way we're thinking about it is: how can we maximise the benefits that each one of these jurisdictions have to offer? Both in terms of access to talent, access to capital, access to non-dilutive funding, etc," 🧪 Joshua Ismin said. Thank you Capital Brief and Hugo Mathers for the feature!

👏 Congratulations, Psylo, for securing AU$12M in their latest seed round, a pivotal step towards commercialisation. Psylo is co-located with the UNSW Science faculty and is pioneering psychedelic-assisted therapy that promises to transform the treatment of depression and other mental health disorders. CEO 🧪 Joshua Ismin said the new capital will fuel further investment in their drug discovery platform, a big leap forward in developing safer, more effective mental health treatments. Stephen Rodda Jamie Conyngham Dax Kukulj Anthony Morfa Marc Wilkins Belinda Ferrari Susan Coppersmith Timothy Schmidt David Burt Greg Ryan Julia Frith Eric Xiaojia Wei Leo Stevens David J. Heffer Dina Titkova

Mark Peplow recently wrote an article published in Nature Portfolio's Nature Biotechnology, highlighting what we've been excited about for quite some time: psychedelic inspired NCEs. Focalpoint Partners's portfolio company, Psylo is mentioned in this article. Psylo's CSO, 💊 Sam Banister was interviewed, his contributions highlighted in yellow and some mentioned here: "In Australia, Psylo has made extensive use of computational modeling to study how hundreds of millions of different molecules fit into the crucial 5-HT2A receptor and designed thousands of potential drug candidates based on the results." "(...) and Banister prefers to call it "psychedelic adjacent (...) Banister is hopeful that [PSYLO-100X] will enter a Phase 1 trial next year." Brom Rector, CFA and I have been extremely excited about the work Psylo is doing - especially as they've worked towards innovating outside of the typical tryptamine and phenethylamine scaffolds. Psylo, Cybin Inc, Gilgamesh Pharmaceuticals, Reunion Neuroscience, Delix Therapeutics, Lophora and Seaport Therapeutics are all doing fantastic work to change the paradigm of CNS drug development. In my opinion, the (1) amount of capital that went into psychedelic-inspired drug discovery and development companies in the past five years and (2) the level of scientific rigor and drug development expertise behind the companies mentioned in this article are more reason to believe that renaissance in psychedelic R&D in pharmaceutical contexts has significantly contributed, if not completely catalyzed, a resurgence of interest in neuropsychiatry. Downloadable link to pdf here: https://lnkd.in/gVmqnPtU 🧪 Joshua Ismin 💊 Sam Banister Brom Rector, CFA